GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (OTCPK:SDZNY) » Definitions » Earnings Yield (Joel Greenblatt) %

Sandoz Group AG (Sandoz Group AG) Earnings Yield (Joel Greenblatt) % : 0.00% (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG Earnings Yield (Joel Greenblatt) %?

Sandoz Group AG's Enterprise Value for the quarter that ended in Dec. 2023 was $17,215 Mil. Sandoz Group AG does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2023. Therefore, GuruFocus does not calculate Sandoz Group AG's Earnings Yield (Joel Greenblatt) at this moment.

The historical rank and industry rank for Sandoz Group AG's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

SDZNY' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 0   Med: 0   Max: 2.32
Current: 1.79

During the past 2 years, the highest Earnings Yield (Joel Greenblatt) of Sandoz Group AG was 2.32%. The lowest was 0.00%. And the median was 0.00%.

SDZNY's Earnings Yield (Joel Greenblatt) % is ranked worse than
54.58% of 1092 companies
in the Drug Manufacturers industry
Industry Median: 2.62 vs SDZNY: 1.79

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Sandoz Group AG's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Sandoz Group AG Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Sandoz Group AG's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG Earnings Yield (Joel Greenblatt) % Chart

Sandoz Group AG Annual Data
Trend Dec22 Dec23
Earnings Yield (Joel Greenblatt) %
- 1.93

Sandoz Group AG Quarterly Data
Dec22 Dec23
Earnings Yield (Joel Greenblatt) % - -

Competitive Comparison of Sandoz Group AG's Earnings Yield (Joel Greenblatt) %

For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sandoz Group AG's Earnings Yield (Joel Greenblatt) % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Sandoz Group AG's Earnings Yield (Joel Greenblatt) % falls into.



Sandoz Group AG Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Sandoz Group AGs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=332/17215.02729
=1.93 %



Sandoz Group AG  (OTCPK:SDZNY) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Sandoz Group AG Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Sandoz Group AG's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sandoz Group AG (Sandoz Group AG) Business Description

Industry
Traded in Other Exchanges
Address
Forum 1, Novartis Campus, Basel, CHE, CH-4056
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as U.S.'s first biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in pipeline.

Sandoz Group AG (Sandoz Group AG) Headlines

From GuruFocus

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research 02-14-2024